Lawyers are expected to discuss how to select a representative group of claims involving Suboxone dental injuries during a meeting with the Court on October 5.
In response to a motion to dismiss filed by Indivior, plaintiffs indicate that the drug maker knew about the risk of tooth decay problems from Suboxone long before the FDA required an update to the label warning.
Lawyers will take actions during the pretrial proceedings that benefit all plaintiffs pursuing tooth decay lawsuits against Suboxone manufacturers, while being mentored by more experienced lawyers in the litigation.
More than 10,000 Suboxone lawsuits have been filed against Indivior, highlighting how the drug maker failed to adequately warn that Suboxone may cause tooth decay.
Suboxone manufacturer attempts to argue that failure to warn and design defect claims over tooth decay risks should be preempted by federal law.
Lawyers have been ordered to submit proposals for exchanging information that will guide the selection of representative Suboxone dental claims for bellwether discovery and test trials.
Doctors were less likely to prescribe opioid addiction medications to Blacks, Latinos and women, CDC researchers discovered.
A tolling agreement for Suboxone tooth decay lawsuits will provide additional time for potential claims to be investigated before they are placed on the MDL docket, where more than 10,000 individual lawsuits may soon have to be filed
As a result of the order, lawsuits over Suboxone tooth decay will move forward with a standard discovery process, preparing a small group of representative cases for early test trials in the federal MDL.
Suboxone lawsuit bundled complaint filed just before two-year anniversary of FDA label warning linking the film strips to tooth decay risks.
